Logo

Transgenomic's Q1 Sales Sag 20 Percent as R&D Grows and Loss Widens

May 11, 2007
NEW YORK (GenomeWeb News) — Transgenomic yesterday said first-quarter revenues decreased 20 percent as R&D spending rose 75 percent and its net loss ballooned by 276 percent.
 
Total receipts for the three months ended March 31 fell to $5.2 million from $6.5 million year over year.
 
However, CEO Craig Tuttle said revenue from Transgenomic’s reference labs grew 277 percent to $290,000. He said the company saw “continuous quarter over quarter growth in our reference laboratory business and improvement in our pharma contract pipeline.”
 
R&D spending rose to $1.1 million from $604,000 million year over year.
 
Transgenomic said its net loss rose to $1.2 million from $318,000 in the year-ago period.
 
Tuttle said he expects “cost-savings measures” to have an increasing impact over the second half of 2007.
 
Transgenomic said it had around $7.9 million in cash and cash equivalents as of March 31.

Breaking News
The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.